FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-04-01

Price

$14.44

-0.14%

Score5.5Watchlist

Signals5/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

FOLD's exceptionally low 1.9% annualized volatility and tight price action are directly tied to its pending acquisition by BioMarin Therapeutics for $14.50 per share in an all-cash deal. Technical signals like QUIET_STORM and STEADY_CLIMB perfectly capture this merger arbitrage dynamic, as the stock is pinned just pennies below the buyout price. Under the current CAUTION (GEOPOLITICAL) macro regime, FOLD is acting as a low-beta safe haven, explaining its +5.4% relative strength against a struggling SPY as investors park capital in the definitive deal.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKWEAK FINISH

Key Takeaways

Merger Arbitrage Play: FOLD is trading at $14.44, representing a tight arbitrage spread against the $14.50 all-cash acquisition price from BioMarin.
Safe Haven Asset: The stock's outperformance versus the SPY is driven by its definitive cash buyout, insulating it from the current geopolitical caution regime.
Deal Risk is the Only Risk: With the transaction expected to close in Q2 2026, the primary threat to the current price is regulatory pushback or deal collapse.

← Back to 2026-04-01 View Full FOLD History →Yahoo Finance &nearr;